Molecular Diagnostics for Infectious Disease. Markets, Strategies and Trends. Volume & Price Forecasts by Pathogen and by Country. With Multiplex and Point of Care Market Analysis, Executive Guides and Customization. 2019 to 2023 - Global Version

  • ID: 4662828
  • Report
  • Region: Global
  • 314 Pages
  • Howe Sound Research
1 of 5
In Spite of the Steady Decline of Disease Prevalence, the Diagnostic Sector Keeps Growing

FEATURED COMPANIES

  • Abbott Diagnostics
  • bioMérieux
  • Curetis
  • Grifols
  • Karius
  • Quidel
  • MORE

Multiplex testing threatens existing infectious disease practice. The microbiology lab may disappear.

The Molecular Diagnostics – Infectious Disease sector of the clinical diagnostics industry is poised for record growth. 

A market that just keeps on growing.  In spite of the steady decline of disease prevalence, the diagnostic sector keeps growing. Find out why in the informative report. And find out about the exciting developments in multiplex assays which threaten to change diagnosis and treatment while limiting the threat of anti microbial drug resistance.

Infectious disease testing directly benefits from the explosion in biotechnology, especially genomics. 

Learn all about it in this new report. A range of dynamic trends are pushing market growth and company valuations.

Trends like:

  • Multiplex testing
  • emerging economies and global prosperity
  • biotechnology advances in genetics
  • pathogen evolution
  • climate change
  • globalization
  • the rise of rapid testing

Exciting technical developments especially in the seesaw between sequencing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.

The report has hundreds of pages of information including a complete list of Current 2016 United States Medicare Fee Payment Schedules to help sharpen your pricing. Again, assistance in using the information is normally provided without additional charges. 

The report includes detailed breakouts for 15 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbott Diagnostics
  • bioMérieux
  • Curetis
  • Grifols
  • Karius
  • Quidel
  • MORE

1. Introduction and Market Definition
1.1 What is Molecular Diagnostics
1.2 The Diagnostics Revolution
1.3 Market Definition
1.3.1 Volumes
1.3.2 Prices
1.3.3 Revenue Market Size
1.4 Methodology
1.4.1 Authors
1.4.2 Sources
1.5 U.S. Medical Market and Clinical Laboratory Testing - Perspective
1.5.1 U.S. Medicare Expenditures for Clinical Testing

2. The Infectious Diseases – Market Analysis by Disease
2.1 HIV - Human Immunodeficiency Virus (AIDS)
2.1.1 Virology
2.1.1.1 Classification
2.1.1.2 Structure and genome
2.1.1.3 Tropism
2.1.1.4 Replication cycle
2.1.1.5 Genetic variability
2.1.2 Diagnosis
2.1.3 Testing
2.1.3.1 Antibody tests
2.1.3.2 Point of Care Tests (POCT)
2.1.3.4 Antigen Tests
2.1.3.5 Nucleic acid-based tests (NAT)
2.1.3.6 Other tests used in HIV treatment
2.1.4 Market Opportunity Analysis
2.2 HBV – Hepatitis B
2.2.1 Virology
2.2.1.1 Genome
2.2.1.2 Pathogenesis
2.2.1.3 Hepatitis B virus replication
2.2.1.4 Serotypes and genotypes
2.2.2 Mechanisms
2.2.3 Diagnosis
2.2.4 Market Opportunity Analysis
2.3 HCV – Hepatitis C
2.3.1 Taxonomy
2.3.2 Structure
2.3.2.2 Genome
2.3.3 Molecular biology
2.3.4 Replication
2.3.5 Genotypes
2.3.5.1 Clinical importance
2.3.6 Market Opportunity Analysis
2.4 HPV - Human papillomavirus
2.4.1 Virology
2.4.1.1 E6/E7 proteins
2.4.1.2 Role in cancer
2.4.1.3 E2 research
2.4.1.4 Latency period
2.4.1.5 Clearance
2.4.2 Diagnosis
2.4.2.1 Cervical testing
2.4.2.2 Oral testing
2.4.2.3 Testing men
2.4.2.4 Other testing
2.4.3 Market Opportunity Analysis
2.5 Influenza
2.5.1 Virology
2.5.1.1 Types of virus
2.5.1.2 Influenzavirus A
2.5.1.3 Influenzavirus B
2.5.1.4 Influenzavirus C
2.5.1.5 Structure, properties, and subtype no
2.5.1.6 Replication
2.5.2 Testing
2.5.2.1 Advantages/Disadvantages of Molecular Assays
2.5.3 Market Opportunity Analysis
2.6 CTGC - Chlamydia/Gonorhea
2.6.1 Gonorrhea
2.6.1.1 Diagnosis
2.6.1.2 Screening
2.6.2 Chlamydia
2.6.2.1 Diagnosis
2.6.2.2 Screening
2.6.3 Testing
2.6.3.1 Nucleic acid amplification tests (NAATs)
2.6.3.2 Performance of NAAT Tests
2.6.4 Market Opportunity Analysis
2.7 Tuberculosis
2.7.1 Mycobacteria
2.7.2 Diagnosis
2.7.2.1 Active tuberculosis
2.7.2.2 Latent tuberculosis
2.7.3 Epidemiology
2.7.4 Molecular Diagnostic Tests
2.7.5 Market Opportunity Analysis
2.8 MRSA - Methicillin-resistant Staphylococcus aureus
2.8.1 Diagnosis
2.8.2 FDA Approved Molecular Tests
2.8.3  Market Opportunity Analysis
2.9 VRE - Vancomycin-resistant Enterococcus
2.9.1 FDA Approved MDx Tests for VRE
2.9.2 Market Opportunity Analysis
2.10 Blood Screening
2.10.1 Collection and Testing
2.10.2 FDA Approved Multiplex Assays
2.10.3 Market Opportunity Analysis

3. Industry Overview
3.1 Industry Participants
3.1.1 IVD Supplier
3.1.2 Independent lab specialized/esoteric
3.1.3 Independent lab national/regional
3.1.4 Independent lab analytical
3.1.5 Public National/regional lab
3.1.6 Hospital lab
3.1.7 Physician lab
3.1.8 Audit body
3.2 The Clinical Laboratory Market Segments
3.2.1 Traditional Market Segmentation
3.2.2 Laboratory Focus and Segmentation
3.3 Industry Structure
3.3.1 Hospital Testing Share
3.3.2 Economies of Scale
3.3.2.1 Hospital vs. Central Lab
3.3.3 Physician Office Lab’s
3.3.4 Physician’s and POCT
3.4 Profiles of Key MDx Companies
Abbott Diagnostics
BD Diagnostics
Beckman Coulter
Biocartis
bioMérieux
Bio-Rad Laboratories
Cepheid
Chembio
Curetis
DiaSorin
Eiken Chemical
Genedrive
Grifols
Hologic
Illumina
Janssen Diagnostics
Karius
Luminex
Meridian Bioscience
Qiagen
Quidel
Roche Molecular Diagnostics
Seegene
Siemens Healthineers
Thermo Fisher

4. Market Trends
4.1 Factors Driving Growth
4.1.1 New Genotypes Creating New Markets
4.1.2 Aging Population a Boon for All Diagnostics
4.1.3 Developing World Driving ID Dx Growth
4.1.4 Point of Care – Why Centralization is Losing Steam
4.1.5 Self Testing
4.1.6 The Need for Speed
4.2 Factors Limiting Growth
4.2.1 Lower Costs
4.2.2 Infectious Disease is Declining.
4.2.3 Wellness Hurts
4.2.4 Economic Growth improves Living Standards
4.3 Instrumentation and Automation
4.3.1 Instruments Key to Market Share
4.3.2 The Shrinking Machine
4.3.2 Multiplex, Point of Care and The Speed Factor
4.4 Diagnostic Technology Development
4.4.1 The Sepsis Testing Market – A New Direction?
4.4.2 POCT/Self Testing as a Disruptive Force
4.4.3 The Genetics Play – One Test for All Known Infections
4.4.4 Antibiotic Resistance Genes – Simplifying Diagnostics

5. Molecular Dx – Infectious Disease Recent Developments
5.1 Recent Developments – Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
5.2 Karius Test To Be Available in Brazil
5.3 Panagene’s STD kit gains Approval
5.4 Startup Prominex Raises $4M in Series A1
5.5 Quidel Receives FDA Clearance for Its Point-of-Care Sofia® Lyme Fluorescent Immunoassa
5.6 'Origami' diagnostics breakthrough set to benefit developing-world farmers
5.7 NYU researchers adapt HIV test to Zika virus
5.8 GA-EMS receives diagnostic device contract
5.9 Biocartis & Immunexpress Sign Partnership for Sepsis
5.10 PerkinElmer to Acquire Euroimmun for $1.3B
5.11 Alveo Closes Financing to Create Accessible Diagnostics Devices
5.12 Siemens Healthineers completes takeover of Fast Track Diagnostics
5.13 Sekisui Diagnostics Enters Strategic Alliance with Mesa Biotech Inc
5.14 Chembio and FIND to Develop Point-of-Care Multiplex Test
5.15 Locus Biosciences and IDbyDNA Partner to Develop Companion Diagnostic Test
5.16 Alere bags FDA nod for rapid flu diagnostic
5.17 FDA approves tests of tick-borne disease to protect blood supply
5.18 Qiagen Trichomonas Assay Gets CE Mark
5.19 Vela Diagnostics HSV Test Gets FDA Clearance
5.20  QIAGEN enters into agreement to acquire STAT-Dx
5.21 Bruker to Acquire Majority Stake in Infectious Disease MDx Firm Hain
5.22 Applied BioCode’s Syndromic Gastrointestinal Pathogen Panel Approved by the FDA
5.23 Ares Genetics to develop AI diagnostic test for infectious diseases
5.24 FDA Considers Guidelines for NGS-Based Infectious Disease Diagnostics

6.  Country Market Sizes – North America
6.1 United States of America
6.1.1 HIV – Volumes, Prices, Revenues
6.1.2 HBV – Volumes, Prices, Revenues
6.1.3 HCV – Volumes, Prices, Revenues
6.1.4 HPV – Volumes, Prices, Revenues
6.1.5 FLU – Volumes, Prices, Revenues
6.1.6 CHGC – Volumes, Prices, Revenues
6.1.7 Tb – Volumes, Prices, Revenues
6.1.8 MRSA – Volumes, Prices, Revenues
6.1.9 VRE – Volumes, Prices, Revenues
6.1.10 Screening/Other – Volumes, Prices, Revenues
6.2 Canada
6.2.1 HIV – Volumes, Prices, Revenues
6.2.2 HBV – Volumes, Prices, Revenues
6.2.3 HCV – Volumes, Prices, Revenues
6.2.4 HPV – Volumes, Prices, Revenues
6.2.5 FLU – Volumes, Prices, Revenues
6.2.6 CHGC – Volumes, Prices, Revenues
6.2.7 Tb – Volumes, Prices, Revenues
6.2.8 MRSA – Volumes, Prices, Revenues
6.2.9 VRE – Volumes, Prices, Revenues
6.2.10 Screening/Other – Volumes, Prices, Revenues

7. Country Markets – Europe
7.1 France
7.1.1 HIV – Volumes, Prices, Revenues
7.1.2 HBV – Volumes, Prices, Revenues
7.1.3 HCV – Volumes, Prices, Revenues
7.1.4 HPV – Volumes, Prices, Revenues
7.1.5 FLU – Volumes, Prices, Revenues
7.1.6 CHGC – Volumes, Prices, Revenues
7.1.7 Tb – Volumes, Prices, Revenues
7.1.8 MRSA – Volumes, Prices, Revenues
7.1.9 VRE – Volumes, Prices, Revenues
7.1.10 Screening/Other – Volumes, Prices, Revenues
7.2 Germany
7.2.1 HIV – Volumes, Prices, Revenues
7.2.2 HBV – Volumes, Prices, Revenues
7.2.3 HCV – Volumes, Prices, Revenues
7.2.4 HPV – Volumes, Prices, Revenues
7.2.5 FLU – Volumes, Prices, Revenues
7.2.6 CHGC – Volumes, Prices, Revenues
7.2.7 Tb – Volumes, Prices, Revenues
7.2.8 MRSA – Volumes, Prices, Revenues
7.2.9 VRE – Volumes, Prices, Revenues
7.2.10 Screening/Other – Volumes, Prices, Revenues
7.3 United Kingdom
7.3.1 HIV – Volumes, Prices, Revenues
7.3.2 HBV – Volumes, Prices, Revenues
7.3.3 HCV – Volumes, Prices, Revenues
7.3.4 HPV – Volumes, Prices, Revenues
7.3.5 FLU – Volumes, Prices, Revenues
7.3.6 CHGC – Volumes, Prices, Revenues
7.3.7 Tb – Volumes, Prices, Revenues
7.3.8 MRSA – Volumes, Prices, Revenues
7.3.9 VRE – Volumes, Prices, Revenues
7.3.10 Screening/Other – Volumes, Prices, Revenues
7.4 Spain
7.4.1 HIV – Volumes, Prices, Revenues
7.4.2 HBV – Volumes, Prices, Revenues
7.4.3 HCV – Volumes, Prices, Revenues
7.4.4 HPV – Volumes, Prices, Revenues
7.4.5 FLU – Volumes, Prices, Revenues
7.4.6 CHGC – Volumes, Prices, Revenues
7.4.7 Tb – Volumes, Prices, Revenues
7.4.8 MRSA – Volumes, Prices, Revenues
7.4.9 VRE – Volumes, Prices, Revenues
7.4.10 Screening/Other – Volumes, Prices, Revenues
7.5 Italy
7.5.1 HIV – Volumes, Prices, Revenues
7.5.2 HBV – Volumes, Prices, Revenues
7.5.3 HCV – Volumes, Prices, Revenues
7.5.4 HPV – Volumes, Prices, Revenues
7.5.5 FLU – Volumes, Prices, Revenues
7.5.6 CHGC – Volumes, Prices, Revenues
7.5.7 Tb – Volumes, Prices, Revenues
7.5.8 MRSA – Volumes, Prices, Revenues
7.5.9 VRE – Volumes, Prices, Revenues
7.5.10 Screening/Other – Volumes, Prices, Revenues
7.6 Switzerland
7.6.1 HIV – Volumes, Prices, Revenues
7.6.2 HBV – Volumes, Prices, Revenues
7.6.3 HCV – Volumes, Prices, Revenues
7.6.4 HPV – Volumes, Prices, Revenues
7.6.5 FLU – Volumes, Prices, Revenues
7.6.6 CHGC – Volumes, Prices, Revenues
7.6.7 Tb – Volumes, Prices, Revenues
7.6.8 MRSA – Volumes, Prices, Revenues
7.6.9 VRE – Volumes, Prices, Revenues
7.6.10 Screening/Other – Volumes, Prices, Revenues
7.7 Czech Republic
7.7.1 HIV – Volumes, Prices, Revenues
7.7.2 HBV – Volumes, Prices, Revenues
7.7.3 HCV – Volumes, Prices, Revenues
7.7.4 HPV – Volumes, Prices, Revenues
7.7.5 FLU – Volumes, Prices, Revenues
7.7.6 CHGC – Volumes, Prices, Revenues
7.7.7 Tb – Volumes, Prices, Revenues
7.7.8 MRSA – Volumes, Prices, Revenues
7.7.9 VRE – Volumes, Prices, Revenues
7.7.10 Screening/Other – Volumes, Prices, Revenues
7.8 Belgium
7.8.1 HIV – Volumes, Prices, Revenues
7.8.2 HBV – Volumes, Prices, Revenues
7.8.3 HCV – Volumes, Prices, Revenues
7.8.4 HPV – Volumes, Prices, Revenues
7.8.5 FLU – Volumes, Prices, Revenues
7.8.6 CHGC – Volumes, Prices, Revenues
7.8.7 Tb – Volumes, Prices, Revenues
7.8.8 MRSA – Volumes, Prices, Revenues
7.8.9 VRE – Volumes, Prices, Revenues
7.8.10 Screening/Other – Volumes, Prices, Revenues
7.9 Russia
7.9.1 HIV – Volumes, Prices, Revenues
7.9.2 HBV – Volumes, Prices, Revenues
7.9.3 HCV – Volumes, Prices, Revenues
7.9.4 HPV – Volumes, Prices, Revenues
7.9.5 FLU – Volumes, Prices, Revenues
7.9.6 CHGC – Volumes, Prices, Revenues
7.9.7 Tb – Volumes, Prices, Revenues
7.9.8 MRSA – Volumes, Prices, Revenues
7.9.9 VRE – Volumes, Prices, Revenues
7.9.10 Screening/Other – Volumes, Prices, Revenues
7.10 Remainder of Europe and Former Soviet Union
7.10.1 HIV – Volumes, Prices, Revenues
7.10.2 HBV – Volumes, Prices, Revenues
7.10.3 HCV – Volumes, Prices, Revenues
7.10.4 HPV – Volumes, Prices, Revenues
7.10.5 FLU – Volumes, Prices, Revenues
7.10.6 CHGC – Volumes, Prices, Revenues
7.10.7 Tb – Volumes, Prices, Revenues
7.10.8 MRSA – Volumes, Prices, Revenues
7.10.9 VRE – Volumes, Prices, Revenues
7.10.10 Screening/Other – Volumes, Prices, Revenues

8. Country Markets – Asia Pacific
8.1 China
8.1.1 HIV – Volumes, Prices, Revenues
8.1.2 HBV – Volumes, Prices, Revenues
8.1.3 HCV – Volumes, Prices, Revenues
8.1.4 HPV – Volumes, Prices, Revenues
8.1.5 FLU – Volumes, Prices, Revenues
8.1.6 CHGC – Volumes, Prices, Revenues
8.1.7 Tb – Volumes, Prices, Revenues
8.1.8 MRSA – Volumes, Prices, Revenues
8.1.9 VRE – Volumes, Prices, Revenues
8.1.10 Screening/Other – Volumes, Prices, Revenues
8.2 Japan
8.2.1 HIV – Volumes, Prices, Revenues
8.2.2 HBV – Volumes, Prices, Revenues
8.2.3 HCV – Volumes, Prices, Revenues
8.2.4 HPV – Volumes, Prices, Revenues
8.2.5 FLU – Volumes, Prices, Revenues
8.2.6 CHGC – Volumes, Prices, Revenues
8.2.7 Tb – Volumes, Prices, Revenues
8.2.8 MRSA – Volumes, Prices, Revenues
8.2.9 VRE – Volumes, Prices, Revenues
8.2.10 Screening/Other – Volumes, Prices, Revenues
8.3 South Korea
8.3.1 HIV – Volumes, Prices, Revenues
8.3.2 HBV – Volumes, Prices, Revenues
8.3.3 HCV – Volumes, Prices, Revenues
8.3.4 HPV – Volumes, Prices, Revenues
8.3.5 FLU – Volumes, Prices, Revenues
8.3.6 CHGC – Volumes, Prices, Revenues
8.3.7 Tb – Volumes, Prices, Revenues
8.3.8 MRSA – Volumes, Prices, Revenues
8.3.9 VRE – Volumes, Prices, Revenues
8.3.10 Screening/Other – Volumes, Prices, Revenues
8.4 India
8.4.1 HIV – Volumes, Prices, Revenues
8.4.2 HBV – Volumes, Prices, Revenues
8.4.3 HCV – Volumes, Prices, Revenues
8.4.4 HPV – Volumes, Prices, Revenues
8.4.5 FLU – Volumes, Prices, Revenues
8.4.6 CHGC – Volumes, Prices, Revenues
8.4.7 Tb – Volumes, Prices, Revenues
8.4.8 MRSA – Volumes, Prices, Revenues
8.4.9 VRE – Volumes, Prices, Revenues
8.4.10 Screening/Other – Volumes, Prices, Revenues
8.5 Australia
8.5.1 HIV – Volumes, Prices, Revenues
8.5.2 HBV – Volumes, Prices, Revenues
8.5.3 HCV – Volumes, Prices, Revenues
8.5.4 HPV – Volumes, Prices, Revenues
8.5.5 FLU – Volumes, Prices, Revenues
8.5.6 CHGC – Volumes, Prices, Revenues
8.5.7 Tb – Volumes, Prices, Revenues
8.5.8 MRSA – Volumes, Prices, Revenues
8.5.9 VRE – Volumes, Prices, Revenues
8.5.10 Screening/Other – Volumes, Prices, Revenues
8.6 Rest of Asia Pacific
8.6.1 HIV – Volumes, Prices, Revenues
8.6.2 HBV – Volumes, Prices, Revenues
8.6.3 HCV – Volumes, Prices, Revenues
8.6.4 HPV – Volumes, Prices, Revenues
8.6.5 FLU – Volumes, Prices, Revenues
8.6.6 CHGC – Volumes, Prices, Revenues
8.6.7 Tb – Volumes, Prices, Revenues
8.6.8 MRSA – Volumes, Prices, Revenues
8.6.9 VRE – Volumes, Prices, Revenues
8.6.10 Screening/Other – Volumes, Prices, Revenues

9. Country Markets – Latin America, Africa & The Middle East
9.1 Brazil
9.1.1 HIV – Volumes, Prices, Revenues
9.1.2 HBV – Volumes, Prices, Revenues
9.1.3 HCV – Volumes, Prices, Revenues
9.1.4 HPV – Volumes, Prices, Revenues
9.1.5 FLU – Volumes, Prices, Revenues
9.1.6 CHGC – Volumes, Prices, Revenues
9.1.7 Tb – Volumes, Prices, Revenues
9.1.8 MRSA – Volumes, Prices, Revenues
9.1.9 VRE – Volumes, Prices, Revenues
9.1.10 Screening/Other – Volumes, Prices, Revenues
9.2 Mexico
9.2.1 HIV – Volumes, Prices, Revenues
9.2.2 HBV – Volumes, Prices, Revenues
9.2.3 HCV – Volumes, Prices, Revenues
9.2.4 HPV – Volumes, Prices, Revenues
9.2.5 FLU – Volumes, Prices, Revenues
9.2.6 CHGC – Volumes, Prices, Revenues
9.2.7 Tb – Volumes, Prices, Revenues .
9.2.8 MRSA – Volumes, Prices, Revenues
9.2.9 VRE – Volumes, Prices, Revenues
9.2.10 Screening/Other – Volumes, Prices, Revenues
9.3 Remainder of Latin America
9.3.1 HIV – Volumes, Prices, Revenues
9.3.2 HBV – Volumes, Prices, Revenues
9.3.3 HCV – Volumes, Prices, Revenues
9.3.4 HPV – Volumes, Prices, Revenues
9.3.5 FLU – Volumes, Prices, Revenues
9.3.6 CHGC – Volumes, Prices, Revenues
9.3.7 Tb – Volumes, Prices, Revenues
9.3.8 MRSA – Volumes, Prices, Revenues
9.3.9 VRE – Volumes, Prices, Revenues
9.3.10 Screening/Other – Volumes, Prices, Revenues
9.4 Africa & The Middle East
9.4.1 HIV – Volumes, Prices, Revenues
9.4.2 HBV – Volumes, Prices, Revenues
9.4.3 HCV – Volumes, Prices, Revenues
9.4.4 HPV – Volumes, Prices, Revenues
9.4.5 FLU – Volumes, Prices, Revenues
9.4.6 CHGC – Volumes, Prices, Revenues
9.4.7 Tb – Volumes, Prices, Revenues
9.4.8 MRSA – Volumes, Prices, Revenues
9.4.9 VRE – Volumes, Prices, Revenues
9.4.10 Screening/Other – Volumes, Prices, Revenues

10. Global Market Summary
10.1 Global Market
10.1.1 HIV – Volumes, Prices, Revenues
10.1.2 HBV – Volumes, Prices, Revenues
10.1.3 HCV – Volumes, Prices, Revenues
10.1.4 HPV – Volumes, Prices, Revenues
10.1.5 FLU – Volumes, Prices, Revenues
10.1.6 CHGC – Volumes, Prices, Revenues
10.1.7 Tb – Volumes, Prices, Revenues
10.1.8 MRSA – Volumes, Prices, Revenues
10.1.9 VRE – Volumes, Prices, Revenues
10.1.10 Screening/Other – Volumes, Prices, Revenues
Appendices
I. United States Medicare System: 2017 Clinical Laboratory Fees Schedule – National Limit and
Midpoint
II. FDA Approved Human Genetic Tests
III. FDA Approved Microbial Tests
III. FDA Approved Pharmacogenomics Tests
 
Table of Tables

Table 1 Medicare Clinical Lab Expenditures Actual & Forecast 2004 to 2020 ($Billion)
Table 2 Classification of HIV Species
Table 3 HIV Tests - CMS Codes & Prices
Table 4 Current HIV Molecular Tests and Instruments Used
Table 5 HBV Tests - CMS Codes & Prices
Table 6 HCV Tests - CMS Codes & Prices
Table 7 HPV Clearance Rates
Table 8 HPV Tests - CMS Codes & Prices
Table 9 HPV Tests, Technology, Types
Table 10 Types of Influenza Tests
Table 11 Influenza Tests - CMS Codes & Prices
Table 12 FDA Cleared Molecular Assays for Influenza
Table 13 FDA Cleared NAAT CTGC Tests
Table 14 CTGC NAAT Target Sequences and Possible False Reactions
Table 15 CTGC Tests - CMS Codes & Prices
Table 16 FDA Approved MDx Tests for Tuberculosis
Table 17 Tuberculosis Tests - CMS Codes & Prices
Table 18 FDA Approved Tests for MRSA
Table 19 MRSA Tests - CMS Codes & Prices
Table 20 FDA Approved Tests for VRE
Table 21 VRE Tests - CMS Codes & Prices
Table 22 FDA Approved Multiplex Assays
Table 23  Market Players by Type
Table 24 Clinical Laboratory Departments and Segments
Table 25 Laboratory Management Focus – Different Approaches
Table 26 Key Segmentation Variables Going Forward
Table 27 Five Factors Driving Growth
Table 28 Four Factors Limiting Growth
Table 29 Key Diagnostic Laboratory Technology Trends
Table 30 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 31 MDx HBV - Volume Price and Revenue Forecast
Table 32 HCV - Volume Price and  Revenue Forecast
Table 33 HPV - Volume Price and  Revenue Forecast
Table 34 FLU - Volume Price and  Revenue Forecast
Table 35 CHGC - Volume Price and  Revenue Forecast
Table 36 Tb - Volume Price and  Revenue Forecast
Table 37 MRSA - Volume Price and  Revenue Forecast
Table 38 VRE - Volume Price and  Revenue Forecast
Table 39 Screening/Other - Volume Price and  Revenue Forecast
Table 40 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 41 MDx HBV - Volume Price and Revenue Forecast
Table 42 HCV - Volume Price and  Revenue Forecast
Table 43 HPV - Volume Price and  Revenue Forecast
Table 44 FLU - Volume Price and  Revenue Forecast
Table 45 CHGC - Volume Price and  Revenue Forecast
Table 46 Tb - Volume Price and  Revenue Forecast
Table 47 MRSA - Volume Price and  Revenue Forecast
Table 48 VRE - Volume Price and  Revenue Forecast
Table 49 Screening/Other - Volume Price and  Revenue Forecast
Table 50 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 51 MDx HBV - Volume Price and Revenue Forecast
Table 52 HCV - Volume Price and  Revenue Forecast
Table 53 HPV - Volume Price and  Revenue Forecast
Table 54 FLU - Volume Price and  Revenue Forecast
Table 55 CHGC - Volume Price and  Revenue Forecast
Table 56 Tb - Volume Price and  Revenue Forecast
Table 57 MRSA - Volume Price and  Revenue Forecast
Table 58 VRE - Volume Price and  Revenue Forecast
Table 59 Screening/Other - Volume Price and  Revenue Forecast
Table 60 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 61 MDx HBV - Volume Price and Revenue Forecast
Table 62 HCV - Volume Price and  Revenue Forecast
Table 63 HPV - Volume Price and  Revenue Forecast
Table 64 FLU - Volume Price and  Revenue Forecast
Table 65 CHGC - Volume Price and  Revenue Forecast
Table 66 Tb - Volume Price and  Revenue Forecast
Table 67 MRSA - Volume Price and  Revenue Forecast
Table 68 VRE - Volume Price and  Revenue Forecast
Table 69 Screening/Other - Volume Price and  Revenue Forecast
Table 70 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 71 MDx HBV - Volume Price and Revenue Forecast
Table 72 HCV - Volume Price and  Revenue Forecast
Table 73 HPV - Volume Price and  Revenue Forecast
Table 74 FLU - Volume Price and  Revenue Forecast
Table 75 CHGC - Volume Price and  Revenue Forecast
Table 76 Tb - Volume Price and  Revenue Forecast
Table 77 MRSA - Volume Price and  Revenue Forecast
Table 78 VRE - Volume Price and  Revenue Forecast
Table 79 Screening/Other - Volume Price and  Revenue Forecast
Table 80 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 81 MDx HBV - Volume Price and Revenue Forecast
Table 82 HCV - Volume Price and  Revenue Forecast
Table 83 HPV - Volume Price and  Revenue Forecast
Table 84 FLU - Volume Price and  Revenue Forecast
Table 85 CHGC - Volume Price and  Revenue Forecast
Table 86 Tb - Volume Price and  Revenue Forecast
Table 87 MRSA - Volume Price and  Revenue Forecast
Table 88 VRE - Volume Price and  Revenue Forecast
Table 89 Screening/Other - Volume Price and  Revenue Forecast
Table 90 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 91 MDx HBV - Volume Price and Revenue Forecast
Table 92 HCV - Volume Price and  Revenue Forecast
Table 93 HPV - Volume Price and  Revenue Forecast
Table 94 FLU - Volume Price and  Revenue Forecast
Table 95 CHGC - Volume Price and  Revenue Forecast
Table 96 Tb - Volume Price and  Revenue Forecast
Table 97 MRSA - Volume Price and  Revenue Forecast
Table 98 VRE - Volume Price and  Revenue Forecast
Table 99 Screening/Other - Volume Price and  Revenue Forecast
Table 100 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 101 MDx HBV - Volume Price and Revenue Forecast
Table 102 HCV - Volume Price and  Revenue Forecast
Table 103 HPV - Volume Price and  Revenue Forecast
Table 104 FLU - Volume Price and  Revenue Forecast
Table 105 CHGC - Volume Price and  Revenue Forecast
Table 106 Tb - Volume Price and  Revenue Forecast
Table 107 MRSA - Volume Price and  Revenue Forecast
Table 108 VRE - Volume Price and  Revenue Forecast
Table 109 Screening/Other - Volume Price and  Revenue Forecast
Table 110 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 111 MDx HBV - Volume Price and Revenue Forecast
Table 112 HCV - Volume Price and  Revenue Forecast
Table 113 HPV - Volume Price and  Revenue Forecast
Table 114 FLU - Volume Price and  Revenue Forecast
Table 115 CHGC - Volume Price and  Revenue Forecast
Table 116 Tb - Volume Price and  Revenue Forecast
Table 117 MRSA - Volume Price and  Revenue Forecast
Table 118 VRE - Volume Price and  Revenue Forecast
Table 119 Screening/Other - Volume Price and  Revenue Forecast
Table 120 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 121 MDx HBV - Volume Price and Revenue Forecast
Table 122 HCV - Volume Price and  Revenue Forecast
Table 123 HPV - Volume Price and  Revenue Forecast
Table 124 FLU - Volume Price and  Revenue Forecast
Table 125 CHGC - Volume Price and  Revenue Forecast
Table 126 Tb - Volume Price and  Revenue Forecast
Table 127 MRSA - Volume Price and  Revenue Forecast
Table 128 VRE - Volume Price and  Revenue Forecast
Table 129 Screening/Other - Volume Price and  Revenue Forecast
Table 130 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 131 MDx HBV - Volume Price and Revenue Forecast
Table 132 HCV - Volume Price and  Revenue Forecast
Table 133 HPV - Volume Price and  Revenue Forecast
Table 134 FLU - Volume Price and  Revenue Forecast
Table 135 CHGC - Volume Price and  Revenue Forecast
Table 136 Tb - Volume Price and  Revenue Forecast
Table 137 MRSA - Volume Price and  Revenue Forecast
Table 138 VRE - Volume Price and  Revenue Forecast
Table 139 Screening/Other - Volume Price and  Revenue Forecast
Table 140 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 141 MDx HBV - Volume Price and Revenue Forecast
Table 142 HCV - Volume Price and  Revenue Forecast
Table 143 HPV - Volume Price and  Revenue Forecast
Table 144 FLU - Volume Price and  Revenue Forecast
Table 145 CHGC - Volume Price and  Revenue Forecast
Table 146 Tb - Volume Price and  Revenue Forecast
Table 147 MRSA - Volume Price and  Revenue Forecast
Table 148 VRE - Volume Price and  Revenue Forecast
Table 149 Screening/Other - Volume Price and  Revenue Forecast
Table 150 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 151 MDx HBV - Volume Price and Revenue Forecast
Table 152 HCV - Volume Price and  Revenue Forecast
Table 153 HPV - Volume Price and  Revenue Forecast
Table 154 FLU - Volume Price and  Revenue Forecast
Table 155 CHGC - Volume Price and  Revenue Forecast
Table 156 Tb - Volume Price and  Revenue Forecast
Table 157 MRSA - Volume Price and  Revenue Forecast
Table 158 VRE - Volume Price and  Revenue Forecast
Table 159 Screening/Other - Volume Price and  Revenue Forecast
Table 160 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 161 MDx HBV - Volume Price and Revenue Forecast
Table 162 HCV - Volume Price and  Revenue Forecast
Table 163 HPV - Volume Price and  Revenue Forecast
Table 164 FLU - Volume Price and  Revenue Forecast
Table 165 CHGC - Volume Price and  Revenue Forecast
Table 166 Tb - Volume Price and  Revenue Forecast
Table 167 MRSA - Volume Price and  Revenue Forecast
Table 168 VRE - Volume Price and  Revenue Forecast
Table 169 Screening/Other - Volume Price and  Revenue Forecast
Table 170 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 171 MDx HBV - Volume Price and Revenue Forecast
Table 172 HCV - Volume Price and  Revenue Forecast
Table 173 HPV - Volume Price and  Revenue Forecast
Table 174 FLU - Volume Price and  Revenue Forecast
Table 175 CHGC - Volume Price and  Revenue Forecast
Table 176 Tb - Volume Price and  Revenue Forecast
Table 177 MRSA - Volume Price and  Revenue Forecast
Table 178 VRE - Volume Price and  Revenue Forecast
Table 179 Screening/Other - Volume Price and  Revenue Forecast
Table 180 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 181 MDx HBV - Volume Price and Revenue Forecast
Table 182 HCV - Volume Price and  Revenue Forecast
Table 183 HPV - Volume Price and  Revenue Forecast
Table 184 FLU - Volume Price and  Revenue Forecast
Table 185 CHGC - Volume Price and  Revenue Forecast
Table 186 Tb - Volume Price and  Revenue Forecast
Table 187 MRSA - Volume Price and  Revenue Forecast
Table 188 VRE - Volume Price and  Revenue Forecast
Table 189 Screening/Other - Volume Price and  Revenue Forecast
Table 190 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 191 MDx HBV - Volume Price and Revenue Forecast
Table 192 HCV - Volume Price and  Revenue Forecast
Table 193 HPV - Volume Price and  Revenue Forecast
Table 194 FLU - Volume Price and  Revenue Forecast
Table 195 CHGC - Volume Price and  Revenue Forecast
Table 196 Tb - Volume Price and  Revenue Forecast
Table 197 MRSA - Volume Price and  Revenue Forecast
Table 198 VRE - Volume Price and  Revenue Forecast
Table 199 Screening/Other - Volume Price and  Revenue Forecast
Table 200 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 201 MDx HBV - Volume Price and Revenue Forecast
Table 202 HCV - Volume Price and  Revenue Forecast
Table 203 HPV - Volume Price and  Revenue Forecast
Table 204 FLU - Volume Price and  Revenue Forecast
Table 205 CHGC - Volume Price and  Revenue Forecast
Table 206 Tb - Volume Price and  Revenue Forecast
Table 207 MRSA - Volume Price and  Revenue Forecast
Table 208 VRE - Volume Price and  Revenue Forecast
Table 209 Screening/Other - Volume Price and  Revenue Forecast
Table 210 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 211 MDx HBV - Volume Price and Revenue Forecast
Table 212 HCV - Volume Price and  Revenue Forecast
Table 213 HPV - Volume Price and  Revenue Forecast
Table 214 FLU - Volume Price and  Revenue Forecast
Table 215 CHGC - Volume Price and  Revenue Forecast
Table 216 Tb - Volume Price and  Revenue Forecast
Table 217 MRSA - Volume Price and  Revenue Forecast
Table 218 VRE - Volume Price and  Revenue Forecast
Table 219 Screening/Other - Volume Price and  Revenue Forecast
Table 220 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 221 MDx HBV - Volume Price and Revenue Forecast
Table 222 HCV - Volume Price and  Revenue Forecast
Table 223 HPV - Volume Price and  Revenue Forecast
Table 224 FLU - Volume Price and  Revenue Forecast
Table 225 CHGC - Volume Price and  Revenue Forecast
Table 226 Tb - Volume Price and  Revenue Forecast
Table 227 MRSA - Volume Price and  Revenue Forecast
Table 228 VRE - Volume Price and  Revenue Forecast
Table 229 Screening/Other - Volume Price and  Revenue Forecast
Table 230 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 231 MDx HBV - Volume Price and Revenue Forecast
Table 232 HCV - Volume Price and  Revenue Forecast
Table 233 HPV - Volume Price and  Revenue Forecast
Table 234 FLU - Volume Price and  Revenue Forecast
Table 235 CHGC - Volume Price and  Revenue Forecast
Table 236 Tb - Volume Price and  Revenue Forecast
Table 237 MRSA - Volume Price and  Revenue Forecast
Table 238 VRE - Volume Price and  Revenue Forecast
Table 239 Screening/Other - Volume Price and  Revenue Forecast
Table 240 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 241 MDx HBV - Volume Price and Revenue Forecast
Table 242 HCV - Volume Price and  Revenue Forecast
Table 243 HPV - Volume Price and  Revenue Forecast
Table 244 FLU - Volume Price and  Revenue Forecast
Table 245 CHGC - Volume Price and  Revenue Forecast
Table 246 Tb - Volume Price and  Revenue Forecast
Table 247 MRSA - Volume Price and  Revenue Forecast
Table 248 VRE - Volume Price and  Revenue Forecast
Table 249 Screening/Other - Volume Price and  Revenue Forecast
Table 250 HIV Infectious Disease - Volume Price and  Revenue Forecast
Table 251 MDx HBV - Volume Price and Revenue Forecast
Table 252 HCV - Volume Price and  Revenue Forecast
Table 253 HPV - Volume Price and  Revenue Forecast
Table 254 FLU - Volume Price and  Revenue Forecast
Table 255 CHGC - Volume Price and  Revenue Forecast
Table 256 Tb - Volume Price and  Revenue Forecast
Table 257 MRSA - Volume Price and  Revenue Forecast
Table 258 VRE - Volume Price and  Revenue Forecast
Table 259 Screening/Other - Volume Price and  Revenue Forecast
Table 260 2017 Clinical Lab Fee Schedule

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Abbott Diagnostics
  • BD Diagnostics
  • Beckman Coulter
  • Biocartis
  • bioMérieux
  • Bio-Rad Laboratories
  • Cepheid
  • Chembio
  • Curetis
  • DiaSorin
  • Eiken Chemical
  • Genedrive
  • Grifols
  • Hologic
  • Illumina
  • Janssen Diagnostics
  • Karius
  • Luminex
  • Meridian Bioscience
  • Qiagen
  • Quidel
  • Roche Molecular Diagnostics
  • Seegene
  • Siemens Healthineers
  • Thermo Fisher
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll